On August 19, 2025 ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, reported it has initiated research of YB328, a newly identified gut microbe, toward clinical application (Press release, ARC Therapies, AUG 19, 2025, View Source [SID1234655418]). Utilizing its proprietary intellectual property, the company has designated the YB328 strain as ARC0812 (RUX: "Lux") and will proceed with preclinical and human clinical trials to evaluate its administration methods and therapeutic efficacy for potential real-world application.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
YB328 was identified by a research group led by Dr. Hiroyoshi Nishikawa, Chief of the Division of Cancer Immunology at the National Cancer Center Research Institute. This specific bacterial strain was found to be prevalent in the gut microbiota of cancer patients who responded favorably to immune checkpoint inhibitors. In murine models, the presence of YB328 was also associated with activation of anti-tumor immune responses.
Building on these findings, ARC Therapies is now exploring the potential of ARC0812 (RUX) to serve as an immune adjuvant in human cancer immunotherapy. Further studies are underway with a view toward eventual commercialization.
About Immune Adjuvants
Immune adjuvants are agents that enhance the body’s immune response to a specific antigen. When administered alongside an antigen-targeting agent that alone may not provoke a sufficient immune reaction, adjuvants help stimulate immune cells and facilitate the formation of immune memory.